Tirzepatide Modification-Related Impurity Reference Material
Modification-related impurities affect the pharmacokinetic profile of Tirzepatide. Reference materials are required for complete characterisation.
PARENT PEPTIDE
Tirzepatide
MATERIAL TYPE
Modification-Related Impurity
TARGET PURITY
≥85% (HPLC)
EVIDENCE STATUS
PeptiQore Experimental
QUANTITY
DOCUMENTATION
QUALITY CONTEXT
Why This Record Matters
Tirzepatide carries a C20 fatty diacid modification at Lys²⁶. This complex modification architecture creates strategically important impurity opportunities. Specific commercial variant to be selected after technical mapping.
POTENTIAL ORIGIN
Incomplete or aberrant fatty acid modification, linker chemistry issues, or side-chain degradation.
Analytical Data Package
PEPTIQORE APPROACH
TRADITIONAL SUPPLIER
Product → CoA
IMPURITY CLASSIFICATION
Modification-Related ImpurityEVIDENCE STATUS
PeptiQore ExperimentalPARENT PEPTIDE
Tirzepatide Quality Hub →RELATED ANALYTICAL MATERIALS
CUSTOM DEVELOPMENT
Can't Find Your Impurity?
PeptiQore supports custom development of peptide-related impurities, sequence variants and degradation materials.